COMPANION study of digital therapy demonstrates reduced anxiety in patients with pulmonary fibrosis

Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced positive results of the COMPANION study (NCT05330312), investigating the efficacy of AlmeeTM, a 9-week digital cognitive behavioral therapy (CBT) accessed through a smartphone or tablet.

Gyros Protein Technologies introduces Gyrolab Generic Rodent ADA Kit Reagents to support preclinical immunogenicity assessment

May 3, 2024

Anthem Biosciences eyes $397M public offering in India

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

January 7, 2025

Still a Smarter Way

You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter

June 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.